The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Open accessAbstract
Desperately Seeking Glucose: Mutations in oncogenes and tumor suppressor genes allow cancer cells to outgrow their neighboring healthy cells. What microenvironmental conditions provide a selective growth advantage to these cells? Yun et al. (p. 1555 , published online 6 August) identify low glucose availability as a microenvironmental factor driving the acquisition of KRAS oncogenic mutations that allow cancer cells to survive and grow. In genetically matched colorectal cancer cells that differed only in the mutational status of the KRAS oncogene, mutant cells selectively overexpressed glucose transporter-1 and exhibited enhanced glucose uptake and glycolysis. When cells with wild-type KRAS were placed in a low-glucose environment, very few cells survived but most of the survivors expressed high levels of glucose transporter-1, and a small percentage of the survivors had acquired new KRAS mutations. Thus, glucose deprivation may help to drive the acquisition of cell growth–promoting oncogenic mutations during tumor development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gene expression and metabolic flux analyses have shown that it upregulates the expression of the GLUT1 glucose transporter to promote glucose uptake by cells, as well as inducing expression of hexokinase 1 and 2 (HK1 and HK2) rate-limiting enzymes of glycolysis, to increase glycolytic activity27–30 (Fig. 2a).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [30]
In the citing paper
“Oncogenic KRAS or BRAF mutations contribute to the Warburg effect, in part by upregulating GLUT1 (REF46).”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [46]
In the citing paper
“Direct data concerning dose-response characteristics of cancers to glucose are sparse, but it is relevant that most cancers have highly effective upregulated, insulin-independent glucose uptake mechanisms (67) and therefore may not derive a further growth advantage from hyperglycemia.”
From Diabetes and Cancer (2010) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citationras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,346
Self-citationTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Bos J. L., Cancer Res. 49, 4682 (1989).2547513
- Airley R., et al.., Clin. Cancer Res. 7, 928 (2001).11309343
- Yasuda S., et al.., J. Nucl. Med. 42, 989 (2001).11438616
- Delbeke D., et al.., J. Nucl. Med. 38, 1196 (1997).9255148
Cited by
Sorted by citations
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Self-citationOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Metabolic pathways promoting cancer cell survival and growth
Boroughs, L. K., & DeBerardinis, R. J. (2015) · Nature Cell Biology · doi:10.1038/ncb3124 · Cited by 1,499
Targeting cancer metabolism: a therapeutic window opens
Heiden, M. G. V. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,443
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?
Hay, N. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.77 · Cited by 1,152
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,082
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. M. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,075
How cancer metabolism is tuned for proliferation and vulnerable to disruption
Schulze, A., & Harris, A. L. (2012) · Nature · doi:10.1038/nature11706 · Cited by 945
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
“Given that cancer cells with KRAS or BRAF mutations are heavily dependent on glycolysis for survival and growth and that pyruvate, the end product of glycolysis, is a major carbon source for the mitochondrial TCA cycle (7, 21), we hypothesized that inhibition of glycolysis at GAPDH might deplete ATP and thereby induce…”
BackgroundResultInfluentialSelf-citationThe Lin28/let-7 Axis Regulates Glucose Metabolism
Zhu, H., Shyh‐Chang, N., Segrè, A. V., Shinoda, G., Shah, S. P., Einhorn, W. S., Takeuchi, A., Engreitz, J., Hagan, J. P., Kharas, M. G., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.033 · Cited by 916
Kamphorst, J. J., Nofal, M., Commisso, C., Hackett, S. R., Lu, W., Grabocka, E., Vander Heiden, M. G., Miller, G., Drebin, J. A., Bar-Sagi, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2211 · Cited by 893
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kölch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 823
ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway
Zhao, Y., Hu, X., Liu, Y., Dong, S., Wen, Z., He, W., Zhang, S., Huang, Q., & Shi, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0648-1 · Cited by 735
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 731
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3298 · Cited by 691
KRAS: feeding pancreatic cancer proliferation
Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 693
The NAD metabolome — a key determinant of cancer cell biology
Chiarugi, A., Dölle, C., Felici, R., & Ziegler, M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3340 · Cited by 660
Calcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., Cova, A., Canese, R., Jachetti, E., Rossetti, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1272 · Cited by 640
Sun, Q., Chen, X., Ma, J., Peng, H., Wang, F., Zha, X., Wang, Y., Jing, Y., Yang, H., Chen, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014769108 · Cited by 586
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Glucose transporters in cancer – from tumor cells to the tumor microenvironment
Ancey, P., Contat, C., & Meylan, E. (2018) · FEBS Journal · doi:10.1111/febs.14577 · Cited by 531
Li, X., Jiang, Y., Meisenhelder, J., Yang, W., Hawke, D. H., Zheng, Y., Xia, Y., Aldape, K., He, J., Hunter, T. R., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.009 · Cited by 504
Phan, L. M., Yeung, S. J., & Lee, M. H. (2014) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2014.01.001 · Cited by 512
Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growth
Gaglio, D., Metallo, C. M., Gameiro, P. A., Hiller, K., Danna, L. S., Balestrieri, C., Alberghina, L., Stephanopoulos, G., & Chiaradonna, F. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.56 · Cited by 492
The utilization of extracellular proteins as nutrients is suppressed by mTORC1
Palm, W., Park, Y., Wright, K., Pavlova, N. N., Tuveson, D. A., & Thompson, C. B. (2015) · Cell · doi:10.1016/j.cell.2015.06.017 · Cited by 457
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449
Self-citationCornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P., Doudna, J. A., & Corn, J. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 452
Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment
Barron, C. C., Bilan, P. J., Tsakiridis, T. K., & Tsiani, E. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.007 · Cited by 450
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
Targeting cancer vulnerabilities with high-dose vitamin C
Ngo, B., Van Riper, J. M., Cantley, L. C., & Yun, J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0135-7 · Cited by 423
Self-citationMetabolism of pancreatic cancer: paving the way to better anticancer strategies
Qin, C., Yang, G., Yang, J., Ren, B., Wang, H., Chen, G., Zhao, F., You, L., Wang, W., & Zhao, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01169-7 · Cited by 433
Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezène, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219555110 · Cited by 413
The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation
Leprivier, G., Remke, M., Rotblat, B., Dubuc, A. M., Mateo, A.-R. F., Kool, M., Agnihotri, S., El-Naggar, A. M., Yu, B., Somasekharan, S. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.055 · Cited by 428
The ERK and JNK pathways in the regulation of metabolic reprogramming
Papa, S., Choy, P. M., & Bubici, C. (2018) · Oncogene · doi:10.1038/s41388-018-0582-8 · Cited by 394
Four Key Steps Control Glycolytic Flux in Mammalian Cells
Tanner, L. B., Goglia, A. G., Wei, M. H., Sehgal, T., Parsons, L. R., Park, J. O., White, E., Toettcher, J. E., & Rabinowitz, J. D. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.003 · Cited by 383
A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate
Fung, K. Y. C., Cosgrove, L. J., Lockett, T. J., Head, R. J., & Topping, D. L. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512001948 · Cited by 362
The enhancement of glycolysis regulates pancreatic cancer metastasis
Yang, J., Ren, B., Yang, G., Wang, H., Chen, G., You, L., Zhang, T., & Zhao, Y. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03278-z · Cited by 347
Ralph, S. J., Rodríguez‐Enríquez, S., Neužil, J., Saavedra, E., & Moreno‐Sánchez, R. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.008 · Cited by 340
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy
Fendt, S., Frezza, C., & Erez, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0844 · Cited by 327
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Zhu, H., Shah, S. P., Shyh‐Chang, N., Shinoda, G., Einhorn, W. S., Viswanathan, S. R., Takeuchi, A., Grasemann, C., Rinn, J. L., Lopez, M. F., et al. (2010) · Nature Genetics · doi:10.1038/ng.593 · Cited by 310
Padanad, M. S., Konstantinidou, G., Venkateswaran, N., Melegari, M., Rindhe, S., Mitsche, M. A., Yang, C., Batten, K. G., Huffman, K. E., Liu, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.009 · Cited by 312
Kvitek, D. J., & Sherlock, G. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002056 · Cited by 310
The Warburg effect and drug resistance
Bhattacharya, B., Omar, M. F. M., & Soong, R. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13422 · Cited by 303
Wu, L., Jin, Y., Zhao, X., Tang, K., Zhao, Y., Tong, L., Yu, X., Xiong, K., Luo, C., Zhu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.001 · Cited by 301
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer
Hao, Y., Samuels, Y., Li, Q., Krokowski, D., Guan, B.-J., Wang, C., Jin, Z., Dong, B., Cao, B., Feng, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11971 · Cited by 290
Self-citationParmenter, T. J., Kleinschmidt, M., Kinross, K. M., Bond, S. T., Li, J., Kaadige, M. R., Rao, A. D., Sheppard, K. E., Hugo, W., Pupo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0440 · Cited by 291
Dysbiosis of gut microbiota in promoting the development of colorectal cancer
Zou, S., Fang, L., & Lee, M. (2017) · Gastroenterology report · doi:10.1093/gastro/gox031 · Cited by 283
Jia, D., Park, J. E., Jung, K., Levine, H., & Kaipparettu, B. A. (2018) · Cells · doi:10.3390/cells7030021 · Cited by 283
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. Q. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 266
Baccelli, I., Gareau, Y., Lehnertz, B., Gingras, S., Spinella, J.-F., Corneau, S., Mayotte, N., Girard, S., Fréchette, M., Blouin-Chagnon, V., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.003 · Cited by 267
Li, L., & Li, W. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.004 · Cited by 257
Chronic Autophagy Is a Cellular Adaptation to Tumor Acidic pH Microenvironments
Wojtkowiak, J. W., Rothberg, J. M., Kumar, V., Schramm, K. J., Haller, E. M., Proemsey, J. B., Lloyd, M. C., Sloane, B. F., & Gillies, R. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3881 · Cited by 256
Pathological Features and Prognostication in Colorectal Cancer
Chen, K., Collins, G. P., Wang, H., & Toh, J. W. T. (2021) · Current Oncology · doi:10.3390/curroncol28060447 · Cited by 260
Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment
Tanaka, K., Sasayama, T., Irino, Y., Takata, K., Nagashima, H., Satoh, N., Kyotani, K., Mizowaki, T., Imahori, T., Ejima, Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78239 · Cited by 249
DNA Damage, Repair, and Cancer Metabolism
Turgeon, M., Perry, N. J. S., & Poulogiannis, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00015 · Cited by 249
Targeting tumor cell metabolism with statins
Clendening, J. W., & Penn, L. Z. (2012) · Oncogene · doi:10.1038/onc.2012.6 · Cited by 247
Metabolism in physiological cell proliferation and differentiation
Agathocleous, M., & Harris, W. A. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.05.004 · Cited by 245
Hyperglycemia, a Neglected Factor during Cancer Progression
Duan, W., Shen, X., Lei, J., Xu, Q., Yu, Y., Li, R., Wu, E., & Ma, Q. (2014) · BioMed Research International · doi:10.1155/2014/461917 · Cited by 242
Su, X., Shen, Z., Yang, Q., Sui, F., Pu, J., Ma, J., Ma, S., Yao, D., Ji, M., & Hou, P. (2019) · Theranostics · doi:10.7150/thno.35219 · Cited by 239
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T. Y., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 246
TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer
Hua, W., ten Dijke, P., Kostidis, S., Giera, M. A., & Hornsveld, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03398-6 · Cited by 245
The Glycolytic Switch in Tumors: How Many Players Are Involved?
Yu, L., Chen, X., Sun, X., Wang, L., & Chen, S. (2017) · Journal of Cancer · doi:10.7150/jca.21125 · Cited by 240
The Warburg effect: Evolving interpretations of an established concept
Chen, X., Qian, Y., & Wu, S. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.027 · Cited by 234
Zhao, Y., Liu, Y., Li, L., Huang, Q., He, W., Zhang, S., Dong, S., Wen, Z., Rao, J., Liao, W., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0820-2 · Cited by 229
Cancer Metabolism: Current Understanding and Therapies
Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 236
Arora, M. (2013) · Materials and Methods · doi:10.13070/mm.en.3.175 · Cited by 247
Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy
Nenkov, M., Ma, Y., Gaßler, N., & Chen, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126262 · Cited by 226
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13665 · Cited by 214
Mitochondria and Reactive Oxygen Species. Which Role in Physiology and Pathology?
Lenaz, G. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_5 · Cited by 219
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
Zambrano, Á., Molt, M., Uribe, E. A., & Salas, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133374 · Cited by 220
Fang, M., Ou, J., Hutchinson, L., & Green, M. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.010 · Cited by 209
Ras and Rap1: A tale of two GTPases
Shah, S. K., Brock, E. J., Ji, K., & Mattingly, R. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 217
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death
Graham, N. A., Tahmasian, M., Kohli, B., Komisopoulou, E., Zhu, M. X., Vivanco, I., Teitell, M. A., Wu, H., Ribas, A., Lo, R. S., et al. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.20 · Cited by 211
KRAS4A directly regulates hexokinase 1
Amendola, C. R., Mahaffey, J. P., Parker, S. J., Ahearn, I. M., Chen, W.-C., Zhou, M., Court, H., Shi, J., Mendoza, S. L., Morten, M. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1832-9 · Cited by 203
Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy
Wang, G., Yu, Y., Wang, Y., Wang, J., Guan, R., Sun, Y., Shi, F., Gao, J., & Fu, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28436 · Cited by 200
Oncogenic KRAS induces NIX-mediated mitophagy to promote pancreatic cancer
Humpton, T. J., Alagesan, B., DeNicola, G. M., Lu, D., Yordanov, G. N., Leonhardt, C. S., Yao, M. A., Alagesan, P., Zaatari, M. N., Park, Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1409 · Cited by 198
Glucose metabolism in cancer cells
Annibaldi, A., & Widmann, C. (2010) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32833a5577 · Cited by 202
NRAS Mutations Are Rare in Colorectal Cancer
Irahara, N., Baba, Y., Nosho, K., Shima, K., Yan, L., Dias-Santagata, D. C., Iafrate, A. J., Fuchs, C. S., Haigis, K. M., & Ogino, S. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181c93fd1 · Cited by 199
Young, C. D., Lewis, A. S., Rudolph, M. C., Ruehle, M. D., Jackman, M. R., Yun, U. J., Ilkun, O. L., Pereira, R. O., Abel, E. D., & Anderson, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023205 · Cited by 199
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
Kouidhi, S., Ayed, F. B., & Elgaaïed, A. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00353 · Cited by 195
Cancer Metabolism and the Evasion of Apoptotic Cell Death
Sharma, A., Boise, L., & Shanmugam, M. (2019) · Cancers · doi:10.3390/cancers11081144 · Cited by 202
Gain of Glucose-Independent Growth upon Metastasis of Breast Cancer Cells to the Brain
Chen, J., Lee, H.-J., Wu, X., Huo, L., Kim, S.-J., Xu, L., Wang, Y., He, J., Bollu, L. R., Gao, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2268 · Cited by 187
Disorders of cancer metabolism: The therapeutic potential of cannabinoids
Sun, D., Li, X., Nie, S., Liu, J., & Wang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113993 · Cited by 195
Hall, A., Meyle, K. D., Lange, M. K., Klima, M., Sanderhoff, M., Dahl, C., Abildgaard, C., Thorup, K., Moghimi, S. M., Jensen, P. B., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.965 · Cited by 191
KRAS-related proteins in pancreatic cancer
Mann, K. M., Ying, H., Juan, J. M., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 192
Role of Oncogenic K-Ras in Cancer Stem Cell Activation by Aberrant Wnt/β-Catenin Signaling
Moon, B.-S., Jeong, W.-J., Park, J., Kim, T. I., Min, D. S., & Choi, K. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt373 · Cited by 189
Kucharzewska, P., & Belting, M. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.20304 · Cited by 189
Exploiting the bad eating habits of Ras-driven cancersPreprint
White, E. (2013) · Genes & Development · doi:10.1101/gad.228122.113 · Cited by 183
Metadata
- Authors
- Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., Diaz, L. A., Velculescu, V. E., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N.
- Affiliations
- Howard Hughes Medical Institute (US)
- The Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Rajagopalan, Harith
- Vogelstein, Bert
- ORCID
- Venue
- Science
- Published
- 2009-09-18
- Volume
- 325
- Issue
- 5947
- Pages
- 1555-1559
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2820374
- OpenAlex
- W1970766774
- Cited by
- 914
- References
- 42
- Citations by year
- 2026: 21 · 2025: 39 · 2024: 43 · 2023: 47 · 2022: 48 · 2021: 60 · 2020: 70 · 2019: 75 · 2018: 61 · 2017: 60 · 2016: 63 · 2015: 51 · 2014: 87 · 2013: 48 · 2012: 61
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA43460, R37CA043460, P50CA062924, CA 62924)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- glucose deprivation, KRAS mutation, BRAF mutation, GLUT1, glucose transporter 1, colorectal cancer cell lines, tumor progression, glycolysis, glucose uptake, 3-bromopyruvate, transcriptome
- MeSH terms
- Animals, Glucose, Glycolysis, Humans, Mice, Nude, Mutation, Neoplasm Transplantation, Pyruvates, Genes, ras, Transplantation, Heterologous, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Gene Targeting, Lactic Acid, Oligonucleotide Array Sequence Analysis, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Cell Proliferation, Glucose Transporter Type 1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
